Skip to main content
. 2023 Nov 4;13(1):161–178. doi: 10.1007/s40123-023-00829-3

Fig. 1.

Fig. 1

Patient disposition of the global diabetic macular edema cohort. aAll patients who received an IVT-AFL treatment within ± 60 days of the 12-/24-month visit window. FAS, full analysis set; IVT-AFL, intravitreal aflibercept; SAS, safety analysis set